The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

NYSE Euronext Announces Trading Volumes for September 2012 and Other Metrics

<p class='bwalignc'> <i>Trading Volumes in September Down Year-over-Year; Rebound From August 2012 Levels</i> </p>

Wednesday, October 10, 2012

NYSE Euronext Announces Trading Volumes for September 2012 and Other Metrics02:30 EDT Wednesday, October 10, 2012 NEW YORK (Business Wire) -- NYSE Euronext (NYX) today announced trading volumes for its global derivatives and cash equities exchanges for September 20121. Trading volumes in September 2012 were down year-over-year, but rebounded across the four principal trading venues from lower levels recorded in August 2012. Highlights NYSE Euronext global derivatives ADV in September 2012 of 7.7 million contracts decreased 19.4% compared to September 2011, but increased 19.8% from August 2012 levels. NYSE Euronext European derivatives products ADV in September 2012 of 3.5 million contracts decreased 28.2% compared to September 2011, but increased 6.5% from August 2012. Excluding Bclear, NYSE Liffe's trade administration and clearing service for OTC products, European derivatives products ADV decreased 20.9% compared to September 2011, but increased 30.6% from August 2012 levels. NYSE Euronext U.S. equity options ADV of 4.1 million contracts in September 2012 decreased 10.2% compared to September 2011 levels, but increased 33.5% from August 2012. NYSE Euronext's U.S. options exchanges accounted for 26.0% of total U.S. consolidated equity options trading in September 2012, down from 26.8% in September 2011, but up from 24.8% in August 2012. NYSE Liffe U.S. ADV of approximately 83,700 contracts decreased 26.2% compared to September 2011, but increased 32.4% versus August 2012. NYSE Euronext European cash products ADV of 1.4 million transactions in September 2012 decreased 24.2% compared to September 2011, but increased 31.3% from August 2012 levels. NYSE Euronext U.S. cash products handled ADV of 1.7 billion shares in September 2012 decreased 34.7% compared to September 2011, but increased 15.4% compared to August 2012. NYSE Euronext's Tape A matched market share in September 2012 was 31.1%, down from 36.3% in September 2011 and down from 31.6% in August 2012. The preliminary average net revenue per transaction type (as defined below) for each of the primary trading venues in the third quarter of 2012 is included below:       PreliminaryTrading Venue   3Q11   2Q12   3Q12European Derivatives (ex. Bclear)1$0.679$0.674$0.65U.S. Derivatives2$0.154$0.148$0.14European Cash3$0.635$0.519$0.53U.S. Cash4   $0.038   $0.043   $0.0391 Average net revenue per contract, excluding Bclear.2 Average net revenue per contract. Excludes NYSE Liffe U.S. trading volume.3 Average net revenue per transaction.4 Average net revenue per 100 shares handled.Derivatives TradingEuropean Derivatives NYSE Euronext European derivatives products ADV in September 2012 of 3.5 million contracts decreased 28.2% compared to September 2011, but increased 6.5% from August 2012 levels. The 3.5 million in European derivatives futures and options contracts ADV in September 2012 consisted of 2.9 million contracts executed through our full-service LIFFE CONNECT trading platform and 0.6 million contracts, or 16.9%, executed through Bclear, NYSE Liffe's trade administration and clearing service for OTC products. Excluding Bclear, NYSE Liffe's trade administration and clearing service for OTC products, European derivatives products ADV decreased 20.9% compared to September 2011, but increased 30.6% compared to August 2012. In the third quarter of 2012, European derivatives products ADV of 3.4 million contracts was 22.2% below prior year levels. The 3.4 million in futures and options contracts ADV in the third quarter of 2012 consisted of 2.6 million contracts executed through LIFFE CONNECT trading platform and 0.8 million contracts, or 24.5%, executed through Bclear. Year-to-date, European derivatives products ADV of 3.8 million contracts was 20.4% below prior year levels. The 3.8 million in futures and options contracts ADV year-to-date consisted of 2.7 million contracts executed through LIFFE CONNECT trading platform and 1.1 million contracts, or 28.4%, executed through Bclear. Total fixed income products ADV of 2.0 million contracts in September 2012 decreased 21.5% from September 2011, but increased 39.6% from August 2012. In the third quarter of 2012, total fixed income products ADV of 1.7 million contracts was 26.2% below prior year levels. Year-to-date, total fixed income products ADV of 1.8 million contracts was 24.2% below prior year levels. Total equity products (including Bclear) ADV of 1.4 million contracts in September 2012 decreased 37.2% compared to September 2011 and decreased 21.0% from August 2012. The 1.4 million contracts in equity products ADV in September 2012 consisted of 0.8 million contracts in individual equity products ADV and 0.6 million contracts in equity index products ADV. The 0.8 million contracts in individual equity products ADV consisted of 0.4 million in futures contracts, which represented a 59.2% decrease compared to September 2011 and 0.4 million in options contracts, which represented a 18.8% decrease compared to September 2011. The average net rate per contract for individual equity futures contracts is significantly lower than other European derivatives products. In the third quarter of 2012, total equity products ADV of 1.6 million contracts were 19.4% below prior year levels. Year-to-date, total equity products ADV of 1.9 million contracts was 17.4% below prior year levels. Total commodities products ADV of approximately 94,000 contracts in September 2012 increased 2.8% compared to September 2011 and increased 5.7% compared to August 2012. In the third quarter of 2012, total commodities product ADV of 100,000 contracts was 27.7% above prior year levels. Year-to-date, total commodities product ADV of 87,000 contracts was 3.9% above prior year levels.U.S. Derivatives NYSE Euronext U.S. equity options ADV of 4.1 million contracts in September 2012 decreased 10.2% compared to September 2011, but increased 33.5% compared to August 2012. In the third quarter of 2012, U.S. equity options ADV of 3.5 million contracts was 27.4% below prior year levels. Year-to-date, U.S. equity options ADV of 3.9 million contracts was 13.2% below prior year levels. Total U.S. consolidated equity options ADV decreased 7.4% to 15.9 million contracts in September 2012 compared to September 2011, but increased 27.5% compared to August 2012. In the third quarter of 2012, U.S. consolidated equity options ADV of 13.8 million contracts was 25.2% below prior year levels. Year-to-date, U.S. consolidated equity options ADV of 14.9 million contracts was 13.5% below prior year levels. NYSE Euronext's U.S. options exchanges accounted for 26.0% of total U.S. consolidated equity options trading in September 2012, down from 26.8% in September 2011, but up from 24.8% in August 2012. NYSE Liffe U.S. ADV of approximately 83,700 contracts decreased 26.2% compared to September 2011, but increased 32.4% from August 2012. In the third quarter of 2012, U.S. futures and futures options ADV of 66,400 contracts was 43.7% below prior year levels. Year-to-date, U.S. futures and futures options ADV of 78,600 contracts was 1.0% above prior year levels. Cash TradingEuropean Cash NYSE Euronext European cash products ADV of 1.4 million transactions in September 2012 decreased 24.2% compared to September 2011 and increased 31.3% compared to August 2012. September 2012 market share in European Cash products was 68.7%, up from 65.7% in September 2011 and up from 68.2% in August 2012. In the third quarter of 2012, European cash products ADV of 1.3 million transactions was 30.9% below prior year levels. Year-to-date, European cash products ADV of 1.5 million transactions was 12.5% below prior year levels. U.S. Cash NYSE Euronext U.S. cash products handled ADV in September 2012 decreased 34.7% to 1.7 billion shares compared to September 2011, but increased 15.4% from August 2012. In the third quarter of 2012, U.S. cash products handled ADV was 1.6 billion shares, down 39.3% from prior year levels. Year-to-date, U.S. cash products handled ADV was 1.7 billion shares, down 25.8% from prior year levels. NYSE Euronext's Tape A matched market share in September 2012 was 31.1%, down from 36.3% in September 2011 and down from 31.6% in August 2012. Exchange Traded Funds NYSE Euronext U.S. matched exchange-traded funds ADV (included in volumes for Tape B and Tape C) of 200 million shares in September 2012 decreased 52.5% compared to September 2011, but increased 19.2% compared to August 2012. In the third quarter of 2012, NYSE Euronext U.S. matched exchange-traded funds ADV of 186 million shares was 54.6% below prior year levels. Year-to-date, NYSE Euronext U.S. matched exchange-traded funds ADV of 215 million shares was 33.6% below prior year levels. Other Metrics Beginning with the third quarter of 2012, the Financial Industry Regulatory Authority (“FINRA”) will no longer utilize office space and other services provided by NYSE Euronext. As a result, “other revenue” will be lower by approximately $3 million beginning with the third quarter of 2012. The average EUR/USD exchange rate for the third quarter of 2012 of $1.25 represented a decrease of 2.5% from the second quarter of 2012 and a decrease of 11.5% compared to the third quarter of 2011. The average GBP/USD exchange rate for the third quarter of 2012 of $1.58 represented a decrease of 0.1% from the second quarter of 2012 and a decrease of 1.9% compared to the third quarter of 2011. During the third quarter of 2012, a total of 4.7 million shares were repurchased at an average price of $25.46. The current stock repurchase authorization has $128 million remaining as of September 30, 2012. As a result of these repurchases, the weighted average diluted shares outstanding in the third quarter of 2012 was 247 million shares. Please click here for the Monthly Transaction Activity Data Table. About NYSE Euronext NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets - the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca - represent one-third of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more information, please visit: http://www.nyx.com. Disclaimer and Cautionary Note Regarding Forward-Looking Statements This press release may contain forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning NYSE Euronext's plans, objectives, expectations and intentions and other statements that are not historical or current facts. Forward-looking statements are based on NYSE Euronext's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause NYSE Euronext's results to differ materially from current expectations include, but are not limited to: NYSE Euronext's ability to implement its strategic initiatives, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk and U.S. and global competition, and other factors detailed in NYSE Euronext's 2011 Annual Report on Form 10-K and other periodic reports filed with the U.S. Securities and Exchange Commission or the French Autorité des Marchés Financiers. In addition, these statements are based on a number of assumptions that are subject to change. Accordingly, actual results may be materially higher or lower than those projected. The inclusion of such projections herein should not be regarded as a representation by NYSE Euronext that the projections will prove to be correct. This press release speaks only as of this date. NYSE Euronext disclaims any duty to update the information herein. 1 All NYSE Euronext derivatives transactions count buy and sell orders together as a single transaction. NYSE Euronext European equities transactions count each buy and sell order as separate transactions, NYSE Euronext U.S. equities transactions count buy and sell orders together as a single transaction. NYSE EuronextMonthly Volume Summary                         Average Daily VolumeTotal VolumeAverage Daily VolumeTotal Volume   % Chg vs.% Chg vs. (Unaudited; contracts in thousands) Sep-12Sep-11% ChgSep-12Sep-11% ChgYTD 2012YTD 2011YTD 2012YTD 2011   Number of Trading Days - European Cash 20 22 20 22 192 192 Number of Trading Days - European Derivatives 20 22 20 22 193 193 Number of Trading Days - U.S. Markets 19 21 19 21 188 188                                               European Derivatives Products   3,455   4,809   -28.2%   69,105   105,799   -34.7%   3,781   -20.4%   729,643   -20.4%of which Bclear 584 1,179 -50.4% 11,685 25,941 -55.0% 1,075 -12.7% 207,412 -12.7%                                               Total Fixed Income Products   1,998   2,547   -21.5%   39,965   56,029   -28.7%   1,818   -24.2%   350,918   -24.2% Short Term Interest Rate Products 1,841 2,400 -23.3% 36,828 52,801 -30.3% 1,668 -26.2% 321,829 -26.2% Medium and Long Term Interest Rate Products 1 157 147 6.9% 3,138 3,228 -2.8% 151 7.2% 29,089 7.2%                                               Total Equity Products 2   1,363   2,171   -37.2%   27,261   47,760   -42.9%   1,875   -17.4%   361,965   -17.4% Individual Equity Products 814 1,483 -45.1% 16,288 32,636 -50.1% 1,388 -17.1% 267,841 -17.1% Futures 395 967 -59.2% 7,895 21,266 -62.9% 930 -12.6% 179,402 -12.6% Options 420 517 -18.8% 8,393 11,369 -26.2% 458 -25.1% 88,439 -25.1% Equity Index Products 549 687 -20.2% 10,972 15,124 -27.5% 488 -18.0% 94,124 -18.0%   of which Bclear 584 1,179 -50.4% 11,685 25,941 -55.0% 1,075 -12.7% 207,412 -12.7% Individual Equity Products 456 1,065 -57.2% 9,118 23,431 -61.1% 1,000 -13.0% 193,037 -13.0% Futures 382 962 -60.2% 7,650 21,154 -63.8% 904 -13.5% 174,532 -13.5% Options 73 104 -29.1% 1,469 2,277 -35.5% 96 -8.0% 18,505 -8.0% Equity Index Products 128 114 12.5% 2,567 2,509 2.3% 74 -9.3% 14,375 -9.3%                                               Commodity Products   94   91   2.8%   1,879   2,010   -6.5%   87   3.9%   16,761   3.9%                                               U.S. Derivatives Products                                                                                       Equity Options 3                                         NYSE Euronext Options Contracts 4,122 4,588 -10.2% 78,318 96,351 -18.7% 3,857 -13.2% 725,134 -13.7% Total Consolidated Options Contracts 15,863 17,134 -7.4% 301,402 359,818 -16.2% 14,862 -13.5% 2,794,081 -14.0%   NYSE Group Share of Total 26.0% 26.8% 26.0% 26.8% 26.0% 0.1% 26.0% 0.1%                                               NYSE Liffe U.S.                                         Futures and Futures Options Volume* 83.7 113.4 -26.2% 1,673 2,494 -32.9% 78.6 1.0% 15,178.2 0.5%                                               European Cash Products (trades in thousands)   1,426   1,882   -24.2%   28,530   41,402   -31.1%   1,534   -12.5%   294,556   -12.9% Equities 1,377 1,804 -23.7% 27,533 39,684 -30.6% 1,483 -11.9% 284,805 -12.4% Exchange-Traded Funds 14 26 -47.7% 274 576 -52.4% 14 -33.2% 2,650 -33.6% Structured Products 30 47 -35.6% 607 1,037 -41.5% 32 -25.1% 6,125 -25.5% Bonds 6 5 20.5% 116 106 9.5% 5 0.9% 976 0.4%                                               U.S. Cash Products (shares in millions) 5   1,669   2,558   -34.7%   31,720   53,709   -40.9%   1,730   -25.8%   325,180   -26.2%                                               NYSE Listed (Tape A) Issues 4                                         Handled Volume 5 1,218 1,761 -30.8% 23,146 36,976 -37.4% 1,237 -24.8% 232,644 -25.2% Matched Volume 6 1,160 1,678 -30.9% 22,034 35,241 -37.5% 1,173 -24.8% 220,535 -25.2% Total NYSE Listed Consolidated Volume 3,730 4,622 -19.3% 70,866 97,054 -27.0% 3,742 -15.6% 703,537 -16.1%   Share of Total Consolidated Volume Handled Volume 5 32.7% 38.1% -5.4% 32.7% 38.1% -5.4% 33.1% -4.0% 33.1% -4.0% Matched Volume 6 31.1% 36.3% -5.2% 31.1% 36.3% -5.2% 31.3% -3.8% 31.3% -3.8%                                               NYSE Arca, MKT and Regional (Tape B) Listed Issues                                 Handled Volume 5 241 477 -49.5% 4,583 10,025 -54.3% 255 -33.5% 48,029 -33.8% Matched Volume 6 219 432 -49.3% 4,161 9,074 -54.1% 230 -33.5% 43,238 -33.8% Total NYSE Arca & MKT Listed Consolidated Volume 1,048 1,806 -41.9% 19,919 37,916 -47.5% 1,083 -26.9% 203,650 -27.3%   Share of Total Consolidated Volume Handled Volume 5 23.0% 26.4% -3.4% 23.0% 26.4% -3.4% 23.6% -2.3% 23.6% -2.3% Matched Volume 6 20.9% 23.9% -3.0% 20.9% 23.9% -3.0% 21.2% -2.1% 21.2% -2.1%                                               Nasdaq Listed (Tape C) Issues                                         Handled Volume 5 210 319 -34.2% 3,991 6,708 -40.5% 237 -21.8% 44,507 -22.2% Matched Volume 6 181 282 -35.8% 3,443 5,928 -41.9% 202 -22.2% 38,067 -22.6% Total Nasdaq Listed Consolidated Volume 1,796 2,089 -14.1% 34,117 43,874 -22.2% 1,753 -15.6% 329,548 -16.1%   Share of Total Consolidated Volume Handled Volume 5 11.7% 15.3% -3.6% 11.7% 15.3% -3.6% 13.5% -1.1% 13.5% -1.1% Matched Volume 6 10.1% 13.5% -3.4% 10.1% 13.5% -3.4% 11.6% -0.9% 11.6% -0.9%                                               Exchange-Traded Funds 5,7                                         Handled Volume 5 220 465 -52.7% 4,181 9,769 -57.2% 239 -33.6% 45,002 -33.9% Matched Volume 6 200 421 -52.5% 3,796 8,832 -57.0% 215 -33.6% 40,453 -34.0% Total ETF Consolidated Volume 987 1,797 -45.1% 18,758 37,737 -50.3% 1,046 -26.1% 196,741 -26.5%   Share of Total Consolidated Volume Handled Volume 5 22.3% 25.9% -3.6% 22.3% 25.9% -3.6% 22.9% -2.6% 22.9% -2.6% Matched Volume 6 20.2% 23.4% -3.2% 20.2% 23.4% -3.2% 20.6% -2.3% 20.6% -2.3%     1 Data includes currency products. 2 Includes all trading activities for Bclear, NYSE Liffe's clearing service for wholesale derivatives. 3 Includes trading in U.S. equity options contracts, not equity-index options. 4 Includes all volume executed in NYSE Group crossing sessions. 5 Represents the total number of shares of equity securities and ETFs internally matched on the NYSE Group's exchanges or routed to and executed at an external market center. NYSE Arca routing includes odd-lots. 6 Represents the total number of shares of equity securities and ETFs executed on the NYSE Group's exchanges. 7 Data included in previously identified categories. * ADVs calculated with the appropriate number of NYSE Liffe U.S. trading days. Source: NYSE Euronext, Options Clearing Corporation and Consolidated Tape as reported for equity securities. All trading activity is single-counted, except European cash trading which is double counted to include both buys and sells. Please follow us at:Exchanges BlogFacebookLinkedInTwitter NYSE EuronextMedia:Amsterdam, +31-20-550-4488Brussels, +32-2-509-1392Lisbon, +351-217-900-029London, +44-20-7379-2789New York, +1-212-656-2411Paris, +33-1-49-27-11-33orInvestor Relations:New York, +1-212-656-5700